ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2,2,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
3,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
4,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
5,1,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
5,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
